Rogocekib (development code CTX-712) is an investigational oral small-molecule inhibitor of CDC2-like kinases (CLKs), primarily targeting CLK2 with high potency (IC50 of 1.4 nM).
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.